EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Redo–Transcatheter Aortic Valve Replacement With Self-Expanding Valves

Toby Rogers, Vinayak N Bapat, Stanley J Chetcuti, Harold L Dauerman, John K Forrest, Sachin S Goel, Kendra J Grubb, Wah Wah Htun, Rishi Puri, Michael J Reardon, Gilbert H L Tang, Amit N Vora und 3 weitere

JACC: Cardiovascular Interventions · 2026

DOI: 10.1016/j.jcin.2026.07.009 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JACC: Cardiovascular Interventions, 2026. Verfasst von Toby Rogers und 14 weiteren Autor:innen. Beteiligte Einrichtung: Section of Interventional Cardiology, MedStar Washington Hospital Center, Georgetown University, Washington, District of Columbia, USA. Electronic ad…. Hauptthemen laut MEDLINE: Aortic Valve, Aortic Valve Stenosis, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medtronic Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Redo-transcatheter aortic valve replacement (TAVR) for failed transcatheter heart valves is expected to increase, but data on outcomes with self-expanding valves remain limited. OBJECTIVES: The aims of this study were to evaluate procedural, clinical, and quality-of-life outcomes following redo-TAVR using self-expanding Evolut valves and to compare these outcomes with those among a contemporary native TAVR cohort. METHODS: Outcomes after redo-TAVR with Evolut R, Evolut PRO, and Evolut PRO+ valves in the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were analyzed and compared with outcomes after native-valve TAVR using the same valve platform during the same study period. The primary endpoints were all-cause mortality, stroke, and readmission at 30 days and 1 year. RESULTS: Among 439 redo-TAVR patients (mean age 78.9 ± 9.8 years, 63.1% women), procedural complication rates were low. Redo-TAVR reduced transvalvular gradients at 1 year, although gradients remained modestly higher than after native TAVR (11.3 ± 6.1 mm Hg vs 8.2 ± 4.6 mm Hg; P < 0.001). After adjustment, clinical outcomes were similar between redo-TAVR and native TAVR at 30 days (mortality adjusted HR: 0.66 [95% CI: 0.39-1.13; P = 0.129]; stroke adjusted HR: 0.95 [95% CI: 0.54-1.68; P = 0.853]; readmission adjusted HR: 0.88 [95% CI: 0.65-1.20; P = 0.422]) and 1-year (mortality adjusted HR: 0.91 [95% CI: 0.72-1.15; P = 0.441]; stroke adjusted HR: 0.91 [95% CI: 0.63-1.34; P = 0.644]; readmission adjusted HR: 0.92 [95% CI: 0.76-1.13; P = 0.439]). Improvements in functional status and quality of life were observed early after redo-TAVR and were sustained through 1 year. Findings were consistent across prespecified subgroups. CONCLUSIONS: In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR. These findings support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic ValveAortic Valve StenosisHeart Valve ProsthesisTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleHumansMaleHemodynamicsPatient ReadmissionProsthesis DesignQuality of LifeRecovery of FunctionRegistriesReoperationRisk FactorsStrokeTime FactorsTreatment OutcomeUnited States

Stichwörter der Autor:innen

Evolutaortic stenosisredo-TAVRregistry analysisself-expanding valvetranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Section of Interventional Cardiology, MedStar Washington Hospital Center, Georgetown University, Washington, District of Columbia, USA. Electronic address: toby.rogers@medstar.net.
  • Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
  • University of Michigan Health Systems - University Hospital, Ann Arbor, Michigan, USA.
  • University of Vermont Medical Center (Fletcher Allen Health Care), Burlington, Vermont, USA.
  • Department of Internal Medicine (Cardiology), Yale University School of Medicine, Yale Transcatheter Valve Program, Yale-New Haven Hospital, New Haven, Connecticut, USA.
  • Houston Methodist DeBakey Heart & Vascular Center, Houston, Texas, USA.

Förderung

  • Medtronic Inc

Zitieren

APA

Rogers, T., Bapat, V. N., Chetcuti, S. J., Dauerman, H. L., Forrest, J. K., Goel, S. S., Grubb, K. J., Htun, W. W., Puri, R., Reardon, M. J., Tang, G. H. L., Vora, A. N., Yakubov, S. J., Eisenberg, R., & Attizzani, G. F. (2026). Redo–Transcatheter Aortic Valve Replacement With Self-Expanding Valves. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2026.07.009

Vancouver

Rogers T, Bapat VN, Chetcuti SJ, Dauerman HL, Forrest JK, Goel SS, et al. Redo–Transcatheter Aortic Valve Replacement With Self-Expanding Valves. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2026.07.009

BibTeX
@article{Rogers2026,
  author = {Rogers, Toby and Bapat, Vinayak N and Chetcuti, Stanley J and Dauerman, Harold L and Forrest, John K and Goel, Sachin S and Grubb, Kendra J and Htun, Wah Wah and Puri, Rishi and Reardon, Michael J and Tang, Gilbert H L and Vora, Amit N and Yakubov, Steven J and Eisenberg, Ruth and Attizzani, Guilherme F},
  title = {Redo–Transcatheter Aortic Valve Replacement With Self-Expanding Valves},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1016/j.jcin.2026.07.009}
}
Kostenlos starten →